121 related articles for article (PubMed ID: 9274452)
21. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
[TBL] [Abstract][Full Text] [Related]
22. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
23. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
24. Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells.
Marverti G; Ligabue A; Lombardi P; Ferrari S; Monti MG; Frassineti C; Costi MP
Int J Oncol; 2013 Oct; 43(4):1269-80. PubMed ID: 23903781
[TBL] [Abstract][Full Text] [Related]
25. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.
Kikuchi Y; Hirata J; Yamamoto K; Ishii K; Kita T; Kudoh K; Tode T; Nagata I; Taniguchi K; Kuwano M
Jpn J Cancer Res; 1997 Feb; 88(2):213-7. PubMed ID: 9119751
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
[TBL] [Abstract][Full Text] [Related]
27. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
28. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
Ma J; Maliepaard M; Kolker HJ; Verweij J; Schellens JH
Cancer Chemother Pharmacol; 1998; 41(3):186-92. PubMed ID: 9443634
[TBL] [Abstract][Full Text] [Related]
29. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
Loh SY; Mistry P; Kelland LR; Abel G; Harrap KR
Br J Cancer; 1992 Dec; 66(6):1109-15. PubMed ID: 1457352
[TBL] [Abstract][Full Text] [Related]
30. Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro.
Jekunen AP; Shalinsky DR; Hom DK; Albright KD; Heath D; Howell SB
Biochem Pharmacol; 1993 May; 45(10):2079-85. PubMed ID: 8512589
[TBL] [Abstract][Full Text] [Related]
31. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
33. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
Misawa T; Kikkawa F; Maeda O; Obata NH; Higashide K; Suganuma N; Tomoda Y
Jpn J Cancer Res; 1995 Jan; 86(1):88-94. PubMed ID: 7737915
[TBL] [Abstract][Full Text] [Related]
34. Impact of intracellular chloride concentration on cisplatin accumulation in sensitive and resistant GLC4 cells.
Salerno M; Yahia D; Dzamitika S; de Vries E; Pereira-Maia E; Garnier-Suillerot A
J Biol Inorg Chem; 2009 Jan; 14(1):123-32. PubMed ID: 18797938
[TBL] [Abstract][Full Text] [Related]
35. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
36. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
37. Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
Marverti G; Ligabue A; Guerrieri D; Paglietti G; Piras S; Costi MP; Farina D; Frassineti C; Monti MG; Moruzzi MS
Gynecol Oncol; 2010 May; 117(2):202-10. PubMed ID: 20031193
[TBL] [Abstract][Full Text] [Related]
38. Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines.
Kasahara K; Fujimura M; Bando T; Shibata K; Shirasaki H; Matsuda T
Br J Cancer; 1996 Nov; 74(10):1553-8. PubMed ID: 8932334
[TBL] [Abstract][Full Text] [Related]
39. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.
Kuppen PJ; Schuitemaker H; van 't Veer LJ; de Bruijn EA; van Oosterom AT; Schrier PI
Cancer Res; 1988 Jun; 48(12):3355-9. PubMed ID: 2897238
[TBL] [Abstract][Full Text] [Related]
40. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.
Montopoli M; Bellanda M; Lonardoni F; Ragazzi E; Dorigo P; Froldi G; Mammi S; Caparrotta L
Curr Cancer Drug Targets; 2011 Feb; 11(2):226-35. PubMed ID: 21158717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
